Date posted: 15 October 2024
- Inaugural community awards recognise the UK’s most ambitious and innovative start-ups.
- Shortlisted in the ‘Fit for the Future: Healthcare Innovation Award’ category.
BRISTOL, UK, 15th October 2024. Scarlet Therapeutics is delighted to announce that we have been recognised in the inaugural SETSquared community awards. We have been shortlisted in the ‘Fit for the Future: Healthcare Innovation Award’ category alongside four other start-ups.
We are very proud to be recognised in this category. Scarlet’s platform technology is pioneering a new class of therapies based on universal red blood cells. We believe the future of medicine is in our blood!
Now, we need your help! Simply cast your vote for us via the link below.
👉: https://ow.ly/6YI050TJvYl Simply scroll down the list and hit the 👍 button next to Scarlet Therapeutics Ltd.
🗳️ Voting closes Tuesday 5 November
🕙 10 AM
For press enquires please contact:
Alistair Irvine
Tel: +44 75077 86615
Email: press@scarlet-tx.com
Website: www.scarlet-tx.com
LinkedIn: Scarlet Therapeutics Ltd | LinkedIn
About Scarlet Therapeutics
Scarlet Therapeutics is developing a unique platform that generates novel red blood cell-based therapeutics to potentially treat a wide range of diseases. Initially targeted at the rare metabolic diseases, hyperammonemia and hyperoxaluria, this approach could also be used more broadly to target other metabolic diseases, cancer and autoimmune diseases. These therapeutic red blood cells (tRBCs) are very similar to standard red blood cells, which have many advantageous qualities including pervasive reach throughout the body, a long life and the ability to carry the active proteins within the RBC which are shielded from the immune system. Born out of more than a decade of research at the University of Bristol and the learning from the RESTORE clinical study, Scarlet also has an exclusive commercial licence for the widely used BEL-A cell line, which provides an alternative platform technology for production of red blood cells.